R. Nicole Hadas's most recent trade in Akebia Therapeutics Inc. was a trade of 12,016 Common Stock done at an average price of $1.3 . Disclosure was reported to the exchange on May 13, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 May 2024 | 12,016 | 651,243 (0%) | 0% | 1.3 | 15,140 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.58 per share. | 29 Feb 2024 | 5,974 | 663,259 (0%) | 0% | 1.6 | 9,439 | Common Stock |
| Akebia Therapeutics Inc. | Hadas R. Nicole | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.52 per share. | 27 Feb 2024 | 7,411 | 669,233 (0%) | 0% | 1.5 | 11,265 | Common Stock |
| Akebia Therapeutics Inc. | R. Nicole Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 224,000 | 224,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Hadas R. Nicole | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 149,300 | 676,644 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 200,000 | 587,530 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.22 per share. | 24 May 2023 | 63,186 | 524,344 (0%) | 0% | 1.2 | 77,270 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 100,000 | 387,530 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 6,613 | 288,618 (0%) | 0% | 0.9 | 5,803 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 5,333 | 295,231 (0%) | 0% | 0.9 | 4,680 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 1,088 | 287,530 (0%) | 0% | 0.9 | 955 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 27 Feb 2023 | 6,677 | 300,564 (0%) | 0% | 0.8 | 5,430 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 50,000 | 315,748 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 6,873 | 308,875 (0%) | 0% | 2.2 | 14,919 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 6,556 | 302,319 (0%) | 0% | 2.2 | 14,231 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.15 per share. | 28 Feb 2022 | 6,555 | 265,748 (0%) | 0% | 2.2 | 14,125 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 1,078 | 304,241 (0%) | 0% | 2.2 | 2,340 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 01 Apr 2021 | 1,060 | 272,303 (0%) | 0% | 3.4 | 3,604 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 10,192 | 273,363 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 62,000 | 277,456 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 26 Feb 2021 | 7,976 | 263,171 (0%) | 0% | 3.4 | 27,087 | Common Stock |
| Akebia Therapeutics Inc. | Nicole R. Hadas | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 26 Feb 2021 | 6,309 | 271,147 (0%) | 0% | 3.4 | 21,426 | Common Stock |